Our study is the first to utilize the OpenVigil 2.1, a universal novel web-based pharmacovigilance analysis tool to analyze real-life safety and effectiveness of six ADHD medications with special emphasis on psychiatric adverse events. We accounted for the following ADHD medications; atomoxetine, lisdexamphetamine, amphetamine, methylphenidate (instant release, intermediate acting, long acting). We believe that thorough knowledge of adverse events for each medication helps to support treatment guidelines and clinical management of the events.